|
|||
DRUGS & SUPPLEMENTS
|
What are the side effects you encounter while taking this medicine? |
Hydrochlorothiazide:
Olmetor-H (Hydrochlorothiazide) is an antihypertensive, diuretic drug that acts on the electrolyte reabsorption in the renal tubular mechanism increasing the excretion of chloride and sodium in equivalent amounts. The exact mechanism of its antihypertensive action is not known at this time.
Olmetor-H (Hydrochlorothiazide) is typically employed for the treatment of patients suffering from hypertension, either as monotherapy or in combination with other antihypertensive medication. It is also employed in some cases as a diuretic agent. Olmetor-H (Hydrochlorothiazide) therapy may also be prescribed for the treatment of hepatic cirrhosis, edema (in patients suffering from congestive heart failure), nephrotic syndrome, drug induced edema, chronic renal failure or acute glomerulonephritis. Health care professionals may prescribe this drug in order to treat other medical conditions as well; if you would like to know more about the reasons you have been prescribed this drug, it is advised to ask your personal physician.
Olmetor-H (Hydrochlorothiazide) may not be used in the treatment of patients who are allergic to this drug, any of its components or other sulfonamide-derived medication. Also, this drug may not be suitable for use in patients that are suffering from anuria, azotemia or impaired renal functions. Caution should be employed if the patient is suffering from hepatic disease. Other medical conditions may also influence the examining health care provider's decision of prescribing Olmetor-H (Hydrochlorothiazide); it is strongly recommended to make sure that the health care professional is fully aware of your health condition and medical history before starting a treatment with this drug.
Use of Olmetor-H (Hydrochlorothiazide) during pregnancy or breast-feeding is also not recommended. This medicine may affect an unborn baby and it also passes into breast milk. As such, use of this drug in pregnant women or breast-feeding mothers should not be employed.
You should always take Olmetor-H (Hydrochlorothiazide) as you have been directed by the prescribing health care specialist. While in some cases daily administration of the drug is recommended, other patients may be prescribed an intermittent therapy. Also, the number of daily doses may vary. As such, it is best that you do not follow another patient's intake schedule. If you have difficulties understanding the intake guidelines that your prescribing health care professional has provided, you should ask for further explanations from an authorized health care specialist - such as a pharmacist, a doctor or a nurse.
The exact Olmetor-H (Hydrochlorothiazide) dosage may vary greatly from one case to another, depending on the condition being treated, on the patient's medical history and general health condition, on his or her age as well as on a number of other factors. As such you are advised to use the exact Olmetor-H (Hydrochlorothiazide) dosage that has been prescribed to you and never use the dosage prescribed to another patient or a dosage that you have been prescribed in the past. Taking a different Olmetor-H (Hydrochlorothiazide) dose may cause the treatment to not have the desired effect, and if you take this drug in larger doses you may have a higher risk of developing side effects, or you may suffer from an overdose.
You should never exceed the Olmetor-H (Hydrochlorothiazide) prescribed dosage, in order to avoid an overdose with this medication. However, if you consider that you are affected by an overdose with this drug it is advised to immediately consult your personal health care provider, the local poisons center or to go to the nearest medical facility to seek emergency medical attention. The common symptoms of an overdose with Olmetor-H (Hydrochlorothiazide) are dehydration and cardiac arrhythmia. The patient may also suffer from electrolyte depletion and thus may present the relevant signs and symptoms.
In case you have missed a dose of Olmetor-H (Hydrochlorothiazide), it is advised that you take the dose as soon as you remember. If the moment when you remember is too close to another intake of the medication, you should completely skip the missed Olmetor-H (Hydrochlorothiazide) dose and take the next scheduled dose on time. You should never take a larger dose of the drug in order to make up for a missed dose, unless your prescribing health care provider directs you to do so.
In some patients Olmetor-H (Hydrochlorothiazide) may cause side effects. While they are not very common, it is recommended to let your personal health care provider know if you begin experiencing any side effects. Several types of symptoms are possible: dizziness, headache, paresthesias, gastric irritation, anorexia, nausea and vomiting, diarrhea or constipation, pancreatitis, jaundice, hypotension. Metabolic side effects may include glycosuria, hyperglycemia, hyperuricemia, hypokalemia or hyponatremia. Renal failure or dysfunction may develop, as well as interstitial nephritis. Some patients reported experiencing muscle spasms, restlessness, unusual weakness and blurred vision. In some cases photosensitivity, anaphylactic reactions, respiratory distress, fever, rashes, vasculitis or toxic epidermal necrolysis have occurred.
Olmetor-H (Hydrochlorothiazide) may interact with barbiturates and narcotics, as well as with alcohol. If you are also following a treatment course with antidiabetic drugs, their dosage may need to be adjusted before starting to take Olmetor-H (Hydrochlorothiazide). This drug may have an additive effect with other antihypertensive medication. ACE inhibitors, ACTH, corticosteroids and skeletal muscle relaxants may also interact with this drug causing unwanted effects. This drug may not be properly absorbed if the patient is also taking Colestipol resins or Cholestyramine. NSAIDs, lithium and Pressor amines may affect or be affected by Olmetor-H (Hydrochlorothiazide), and as such it is strongly recommended to let the prescribing health care provider know if you are taking these or any other drugs before starting a therapy course with this medicine. Other drug interactions that are not listed here are also possible.
Olmesartan Medoxomil:
Olmetor-H is an antihypertensive agent, angiotensin II receptor blocker. This medication has a high selectivity to angiotensin II receptor type 1 (AT1) which are implemented with the participation of the main effects of angiotensin II. By blocking these receptors Olmetor-H (Olmesartan Medoxomil) prevents and eliminates the vasoconstrictor action of angiotensin II, causes a secondary increase in plasma renin activity due to elimination of negative feedback for renin release and a direct reduction in aldosterone secretion.
When hypertension Olmetor-H (Olmesartan Medoxomil) causes dose-dependent, prolonged reduction of blood pressure.
There are no details about the development of arterial hypotension after the first dose of Olmetor-H (Olmesartan Medoxomil), tachyphylaxis during prolonged treatment and withdrawal.
When taking first time Olmetor-H (Olmesartan Medoxomil) provides an effective and mild reduction of blood pressure within 24 hours. Maximum antihypertensive effect is achieved after 8 weeks of the therapy, although a significant effect of blood pressure lowering marked only in 2 weeks of the treatment.
Olmetor-H (Olmesartan Medoxomil) is a pro-drug. It quickly turns into a pharmacologically active metabolite of olmesartan under the influence of esterases in the intestinal mucosa and blood of portal vein during absorption from the gastrointestinal tract. In blood plasma or secretions nondecomposed Olmetor-H (Olmesartan Medoxomil) or unmodified side chain medoxomil group was not been determined. Cmax of olmesartan in plasma levels reached an average of approximately 2 hours after ingestion and increases almost linearly with increasing dose to 80 mg. Simultaneous ingestion does not affect the bioavailability of olmesartan. Olmesartan binding to plasma proteins is 99.7% but the potential for clinically significant shift values of binding to proteins in the interaction of olmesartan with other drugs that have a high degree of protein binding is low (this is confirmed by the fact that there is no clinically significant interaction between warfarin and olmesartan). Olmesartan is excreted in the urine (approximately 40%) and bile (approximately 60%), T1/2 is 10-15 hours. Cumulation of olmesartan is not marked.
Essential arterial hypertension.
Olmetor-H is administered orally on a daily basis. The initial dose is 10 mg / day. When inefficiency the dose increases up to the optimum 20 mg / day. If necessary the dose may be increased to the maximum 40 mg / day.
For elderly patients dosage adjustment is not required. If necessary increasing the daily dose to a maximum of 40 mg / day improvement should be under careful control of blood pressure. For patients with impaired mild or moderate renal function (creatinine clearance 20-60 ml / min) the maximum daily dose is 20 mg.
Cardio-vascular system: hypotension, angina pectoris.
Hemopoietic system: thrombocytopenia.
CNS: vertigo, dizziness, headache, asthenia syndrome (fatigue, lethargy, malaise).
Respiratory system: bronchitis, pharyngitis, rhinitis, cough.
Digestive system: diarrhea, dyspepsia, gastroenteritis, abdominal pain, nausea, vomiting, increased liver enzymes.
Dermatological reactions: itching, rash, angioedema, atopic dermatitis, facial edema, urticaria.
Musculoskeletal system: arthritis, back pain, bone pain, muscle cramps, myalgia, increased activity of CK.Urinary system: hematuria, urinary tract infection.
Metabolism: hypertriglyceridemia, hyperuricemia, hyperkalemia, increased serum creatinine and urea in serum, peripheral edema.
Other: chest pain, flu-like symptoms.
Obstruction of the biliary tract, pregnancy, lactation, childhood and adolescence under the age of 18 years.
Olmetor-H is contraindicated for use during pregnancy and lactation (breastfeeding).
Due to the lack of sufficient clinical experience does not recommended the use of Olmetor-H (Olmesartan Medoxomil) in patients with severe renal insufficiency (creatinine clearance < 20 mL / min), patients with impaired liver function.
Olmetor-H (Olmesartan Medoxomil) used with caution in patients with stenosis of the aortic or mitral valves or obstructive hypertrophic cardiomyopathy.
In the case of previous intensive therapy with diuretics, human salt-free diet, diarrhea and / or vomiting after the first dose may been developed hypotension as a result of reducing the BCC. Thats why it is necessary to eliminate the possibility of hypovolemia before starting treatment with Olmetor-H (Olmesartan Medoxomil).
Olmetor-H (Olmesartan Medoxomil) should be used with caution for patients with heart failure, kidney disease, renal artery stenosis in both or only one kidney because of the risk of acute hypotension, azotemia, oliguria, acute renal failure.
When treating patients with impaired renal function it is recommended periodic monitoring of potassium and creatinine in serum.
It is not recommended of Olmetor-H (Olmesartan Medoxomil) using in patients with primary hyperaldosteronism.
It should be borne in mind that excessive lowering of blood pressure in patients with coronary artery disease or atherosclerosis of cerebral vessels may lead to the development of myocardial infarction or ischemic stroke.
While taking of Olmetor-H (Olmesartan Medoxomil) occasionally there may be dizziness or fatigue which should be considered in the application of patients, control of vehicles and / or engaged in other potentially hazardous activities.
Simultaneous administration of Olmetor-H (Olmesartan Medoxomil) with:
Symptoms: pronounced reduction in blood pressure, tachycardia.
Treatment: when pronounced reduction of blood pressure is recommended to lay the patient on his back and lifted his legs. There is recommended a gastric lavage and / or reception of activated charcoal therapy aimed at correcting dehydration and violations of water-salt metabolism, supplementation of BCC.
Depending on the reaction of the Olmetor-H after taken, if you are feeling dizziness, drowsiness or any weakness as a reaction on your body, Then consider Olmetor-H not safe to drive or operate heavy machine after consumption. Meaning that, do not drive or operate heavy duty machines after taking the capsule if the capsule has a strange reaction on your body like dizziness, drowsiness. As prescribed by a pharmacist, it is dangerous to take alcohol while taking medicines as it exposed patients to drowsiness and health risk. Please take note of such effect most especially when taking Primosa capsule. It's advisable to consult your doctor on time for a proper recommendation and medical consultations.
Is Olmetor-H addictive or habit forming?Medicines are not designed with the mind of creating an addiction or abuse on the health of the users. Addictive Medicine is categorically called Controlled substances by the government. For instance, Schedule H or X in India and schedule II-V in the US are controlled substances.
Please consult the medicine instruction manual on how to use and ensure it is not a controlled substance.In conclusion, self medication is a killer to your health. Consult your doctor for a proper prescription, recommendation, and guidiance.
There are no reviews yet. Be the first to write one! |
The information was verified by Dr. Rachana Salvi, MD Pharmacology